(EIRGASUN®/HERWENDA®) Trastuzumab Biosimilar

EIRGASUN was officially approved from the Taiwan Food and Drug Administration for EG12014 (Trastuzumab Biosimilar) "EIRGASUN®". This drug approval is for a 150 mg cryo-crystal injection formulation, which approved to use for the indications covered by the control drug Herceptin®, including the treatment of early-stage HER2-positive breast cancer, metastatic breast cancer, and gastric cancer.